

## Product Information

# *o*-Phenylenediamine dihydrochloride

Peroxidase substrate

**P1526**

## Product Description

CAS Registry Number: 615-28-1


Molecular Formula: C<sub>6</sub>H<sub>8</sub>N<sub>2</sub> • 2 HCl

Molecular Weight: 181.06

 $\lambda_{\text{max}}$ : 233 nm, 289 nm (0.1 M Tris, pH 9.0)<sup>1</sup>

Synonyms: 1,2-benzenediamine, OPD

*o*-Phenylenediamine dihydrochloride is a chromogenic substrate that is suitable for use in ELISA procedures that utilize horseradish peroxidase (HRP) conjugates.<sup>3,4</sup> This substrate produces a soluble end product that is orange-brown in color and can be read spectrophotometrically at 450 nm. The OPD reaction may be stopped with 3 M HCl or 3 M H<sub>2</sub>SO<sub>4</sub> solution, and read at 492 nm.



The OPD oxidation product that HRP produces is 2,3-diaminophenazine. 2,3-diaminophenazine has been characterized by melting point, mass spectrometry, and NMR.<sup>5,6</sup>

Several theses<sup>7-10</sup> and dissertations<sup>11-15</sup> have cited use of product P1526 in their research protocols.

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Storage/Stability

Store the product at -20 °C. Protect from heat, light, and moisture. Allow to reach room temperature before use.

## Procedure

1. Dissolve OPD in 0.05 M phosphate-citrate buffer, pH 5.0, to the desired concentration. Typically an OPD concentration of 0.4 mg/mL is used.
2. Immediately prior to use, add 40  $\mu$ L of fresh 30% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) per 100 mL of phosphate-citrate buffer solution.

### Phosphate-citrate buffer

To prepare phosphate-citrate buffer, pH 5.0, mix the following:

- 25.7 mL of 0.2 M dibasic sodium phosphate
- 24.3 mL of 0.1 M citric acid
- 50 mL of deionized water

Adjust the pH to 5.0, if necessary.

Alternatively, capsules of phosphate-citrate buffer with sodium perborate (Cat. No. P4922) may be used. One P4922 capsule is added to 100 mL of deionized water. This yields a 0.05 M phosphate-citrate buffer, with 0.03% sodium perborate as a substitute for H<sub>2</sub>O<sub>2</sub>, so that addition of H<sub>2</sub>O<sub>2</sub> is not necessary.

## Troubleshooting

### If background is too high:

1. Use a blocking step prior to the application of the primary antibody. Normal serum (5% v/v) from the same species as the host of the secondary antibody generally produces the best results.
2. Additional blocking agents for an ELISA are:
  - 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0
  - 1% BSA (bovine serum albumin) containing 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0
  - 3% nonfat-dried milk in 0.01 M PBS (such as Cat. No. P2194). Do not use milk as a blocking agent when using avidin-biotin systems.
3. Use 0.05% TWEEN® 20 in all washing and antibody diluent buffers.

- Run control wells without the primary antibody to check for non-specific reactivity of the secondary antibody.
- Titer the primary antibody and the conjugate to optimize working dilutions.

**If no color develops, or the color is too faint:**

- Adjust the concentration of the primary antibody.
- Adjust the concentration of the secondary antibody.
- Determine if the enzyme conjugate is active by mixing a small sample of substrate and conjugate together in a test tube.
- Increase the reaction time or temperature.
- Adjust the concentration of the coating antigen.
- Consider using an amplification system such as avidin-biotin.

## References

- Doub, L., and Vandenbelt, J.M., *J. Am. Chem. Soc.*, **71(7)**, 2414-2420 (1949).
- The Merck Index*, 12th ed., Entry# 7438 (1996).
- Wolters, G. et al., *J. Clin. Path.*, **29(10)**, 873-879 (1976).
- Bovaird, J.H. et al., *Clin. Chem.*, **28(12)**, 2423-2426 (1982).
- Tarcha, P.J. et al., *Anal. Biochem.*, **165(1)**, 230-233 (1987).
- Bystryak, S.M., and Mekler, V.M., *Anal. Biochem.*, **202(2)**, 390-393 (1992).
- Frank, Daniel Patrick, "A Series of Laboratory Exercises for Use in Undergraduate Studies". The College at Brockport (State University of New York), M.S. thesis, p. 58 (1988).
- O'Brien, Thomas William, "The development of monoclonal antibodies to the isozymes of malate dehydrogenase, with laboratory applications". The American University, M.S. thesis, p. 8 (1991).
- Bulsara, Jignesh, "Synthesis and Analysis of Hetero-Divalent Oligosaccharides". University of Alberta, M.Sc. thesis, p. 127 (2004).
- Dewaele, Aurélie, "Towards better diagnosis and treatment of thrombotic thrombocytopenic purpura". KU Leuven, M.Sc. thesis, p. 36 (2019).
- Siwak, Edward B., "Detection, isolation, and characterization of human rotavirus (HRV) isolated from patients at two hospitals on Oahu". University of Hawaii, Ph.D. dissertation, p. 50 (1990).

- Goldblatt, David, "Qualitative and Quantitative aspects of Human IgG subclass responses with special reference to a common microorganism, *Moraxella (Branhamella) catarrhalis*". University of London, Ph.D. dissertation, p. 44 (1991).
- Furrie, Elizabeth, "Intestinal modification of a protein antigen and its effect on oral tolerance induction". University of London, Ph.D. dissertation, p. 44 (1993).
- Preller, Liesbeth, "Respiratory health effects in pig farmers: assessment of exposure and epidemiological studies of risk factors". Rijksuniversiteit Utrecht, Ph.D. dissertation, p. 156 (1995).
- Bishop, Kenneth D., "Egr-2 and PD-1 Are Required for Induction and Maintenance of T Cell Anergy". University of Massachusetts Medical School, Ph.D. dissertation, p. 58 (2005).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

### Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

### Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

### Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

P1526pis Rev 03/22 CMH,RXR,GCY

**MILLIPORE  
SIGMA**